ReportWire

Tag: Opioids

  • Review: A portrait of an artist in Venice-winning doc

    Review: A portrait of an artist in Venice-winning doc

    [ad_1]

    Nan Goldin, the subject of Laura Poitras’ Venice Film Festival-winning documentary “ All the Beauty and the Bloodshed,” is a name you probably either know well or not at all. In the art world, she is unequivocally famous. Her photographs depicting downtown life in the late 1970s and ’80s and the vibrant, glamorous bohemians she encountered on the scene, like John Waters It-Girl Cookie Mueller, have been displayed at the Whitney, the Tate and MoMA.

    To look at any of the photos in her most well-known work, the ever-evolving slideshow “The Ballad of Sexual Dependency,” you can see how influential she was on generations to come with her raw, public-private snapshots of parties that didn’t end until dawn, beautiful “queens” and even her face, one month after a “dope-sick” boyfriend beat her so badly she almost lost her eye. The New York Times review of a collection of those photographs at the time said that “The Ballad” was to the 1980s what Robert Frank’s “The Americans” was to the 1950s. And it would become a devastating document of many of the young lives lost in the AIDS epidemic.

    This is only part of Goldin’s story, as you’ll learn in “ All the Beauty and the Bloodshed,” which begins its theatrical run this week in New York before expanding to more markets in the coming weeks. Poitras, the Oscar-winning filmmaker behind “ Citizenfour,” started filming Goldin to document her protest efforts against museums accepting money from the Sackler family. Their company, Purdue Pharma, developed and marketed the widely prescribed and widely abused painkiller OxyContin, the brand name for the opioid oxycodone. Opioids, which also include fentanyl, have been linked to more than 500,000 deaths in the U.S. over the past two decades.

    Goldin several years ago found herself addicted to opioids which she was prescribed for a surgery and took according to instructions. But, she said, she became addicted overnight. When she got out of treatment, she started reading about Purdue and the Sacklers, a name she associated with museums and philanthropy. Sackler-run foundations have given many millions of dollars to some of the world’s most prestigious museums and universities, from the Guggenheim to Oxford. And her mission became clear: To use her status in the art world to get museums to stop accepting money from the Sacklers, take down their name from galleries and to change how we think about addiction and treatment. And partially as a result of her efforts, many museums from the Louvre to the Met, have distanced themselves from the Sacklers.

    Poitras smartly saw that there was a very clear through-line from what Goldin did in the ’80s, when she came out of rehab and saw all her friends dying of AIDS, and what she was doing now. The documentary weaves together these threads to make a holistic portrait of an artist’s battle cry.

    Though the Sackler protests are the hook, the film’s strongest portions are its historical ones. Poitras artfully overlays Goldin’s heartbreaking eloquence with her photographs and a camera shutter soundtrack. Goldin speaks about everything from her stifling childhood in suburbia to the ripple effect of her older sister Barbara’s teenage institutionalization to her death by suicide at age 18 that left Nan, then Nancy Goldin, bouncing between foster homes. It wasn’t until she found a camera that she found her voice and her true family (her friends).

    There are some particularly devastating family realizations that Poitras and Goldin save for last. It’s trite to call that an origin story, but with Goldin, everything stemmed from those confusing days. She’d been told early on never to let the neighbors know about their troubles. Brushing it under the rug, not talking about it and not dealing with it would destroy them, though.

    Goldin might not have known it when she started photographing her LGBTQ friends, but her work has always been about looking at the so-called fringe cultures in society, about showing the problems that the masses would rather just ignore and making them so urgent that you can’t look away anymore. It is an act of hope in the idea that things could be better because the alternative, the silence, is infinitely worse. Goldin would know.

    As Goldin says at the start, “It’s easy to make your life into a story. But it’s harder to sustain real memories.”

    “The real memories are what affect me now,” she continued. “Even if you don’t actually unleash the memories, the effect is there, it’s in your body.”

    “All the Beauty and the Bloodshed,” a NEON release in limited release now, expanding on, has not been rated by the Motion Picture Association. Running time: 117 minutes. Three and a half stars out of four.

    ———

    In a story published Nov. 25, 2022, reviewing “All the Beauty and the Bloodshed,” The Associated Press erroneously reported that OxyContin had been responsible for more than 500,000 overdose deaths in the U.S. That death toll is attributed generally to opioids, which include oxycodone and fentanyl.

    ———

    Follow AP Film Writer Lindsey Bahr on Twitter: www.twitter.com/ldbahr.

    [ad_2]

    Source link

  • A Vaccine Against Deadly Fentanyl Might Be Near

    A Vaccine Against Deadly Fentanyl Might Be Near

    [ad_1]

    By Cara Murez 

    HealthDay Reporter

    THURSDAY, Nov. 17, 2022 (HealthDay News) — Researchers report they have created a vaccine to fight fentanyl addiction, in a potential breakthrough in the opioid epidemic.

    The shot would block the ability of fentanyl to enter the brain and cause the “high” that users crave. It could be used to prevent relapses in people trying to quit opioids, once it gets through clinical trials, the scientists said.

    “We believe these findings could have a significant impact on a very serious problem plaguing society for years — opioid misuse,” said study author Colin Haile, a research associate professor of psychology at the University of Houston and the Texas Institute for Measurement, Evaluation and Statistics.

    “Our vaccine is able to generate anti-fentanyl antibodies that bind to the consumed fentanyl and prevent it from entering the brain, allowing it to be eliminated out of the body via the kidneys. Thus, the individual will not feel the euphoric effects and can ‘get back on the wagon’ to sobriety,” Haile explained in a university news release.

    The team has tested the drug on animals but plans to start manufacturing a clinical-grade vaccine in the coming months and to start human trials. However, research in animals does not always pan out in humans.

    More than 150 people die every day in the United States from overdoses of synthetic opioids including fentanyl. About 80% of people who try to quit suffer a relapse.

    Fentanyl is 50 times stronger than heroin and 100 times stronger than morphine. Even a tiny amount, 2 milligrams, is likely to cause death.

    Scientists created the vaccine using a derivative from E. coli bacteria, to help boost immune response to the vaccine.

    “The anti-fentanyl antibodies were specific to fentanyl and a fentanyl derivative, and did not cross-react with other opioids, such as morphine. That means a vaccinated person would still be able to be treated for pain relief with other opioids,” Haile said.

    Even people who don’t ordinarily consume fentanyl but who use other drugs sometimes experience fentanyl overdoses because the drug is often added to street drugs like cocaine, methamphetamine, counterfeit benzodiazepines like Xanax, and other opioids, such as oxycodone and hydrocodone.

    Opioid use disorder is treated with a mix of medications, including methadone, buprenorphine and naltrexone, the researchers noted. 
     

    This new vaccine could be a “game-changer,” said Therese Kosten, director of the developmental, cognitive & behavioral neuroscience program at the University of Houston (UH).

    “Fentanyl use and overdose is a particular treatment challenge that is not adequately addressed with current medications because of its pharmacodynamics, and managing acute overdose with the short-acting naloxone is not appropriately effective as multiple doses of naloxone are often needed to reverse fentanyl’s fatal effects,” said Kosten, who was senior author of the study.

    Others on the research team were Greg Cuny, a professor of drug discovery at the UH College of Pharmacy and researchers from Baylor College of Medicine and the Michael E. DeBakey Veteran’s Affairs Medical Center, both also in Houston.

    The findings were published online recently in the journal Pharmaceutics.

    Funding was provided by the U.S. Department of Defense through the Alcohol and Substance Abuse Disorders Program managed by RTI International’s Pharmacotherapies for Alcohol and Substance Use Disorders Alliance.

    More information

    The U.S. Centers for Disease Control and Prevention has more on preventing opioid use disorder.

     

     

    SOURCE: University of Houston, news release, Nov. 14, 2022

    [ad_2]

    Source link

  • Walmart offers to pay $3.1 billion to settle opioid lawsuits

    Walmart offers to pay $3.1 billion to settle opioid lawsuits

    [ad_1]

    Walmart proposed a $3.1 billion legal settlement on Tuesday over the toll of powerful prescription opioids sold at its pharmacies, becoming the latest major drug industry player to promise major support to state, local and tribal governments still grappling with a crisis in overdose deaths.

    The retail giant’s announcement follows similar proposals on Nov. 2 from the two largest U.S. pharmacy chains, CVS Health and Walgreen Co., which each said they would pay about $5 billion.

    Most of the drugmakers that produced the most opioids and the biggest drug distribution companies have already reached settlements. With the largest pharmacies now settling, it represents a shift in the opioid litigation saga. For years, the question was whether companies would be held accountable for an overdose crisis that a flood of prescription drugs helped spark.

    With the crisis still raging, the focus now is on how the settlement dollars — now totaling more than $50 billion — will be used and whether they will help curtail record numbers of overdose deaths, even as prescription drugs have become a relatively small portion of the epidemic.

    Bentonville, Arkansas-based Walmart said in a statement that it “strongly disputes” allegations in lawsuits from state and local governments that its pharmacies improperly filled prescriptions for the powerful prescription painkillers. The company does not admit liability with the settlement, which would represent about 2% of its quarterly revenue.

    “Walmart believes the settlement framework is in the best interest of all parties and will provide significant aid to communities across the country in the fight against the opioid crisis, with aid reaching state and local governments faster than any other nationwide opioid settlement to date,” the company said in a statement.

    Lawyers representing local governments said the company would pay most of the settlement over the next year if it is finalized.

    New York Attorney General Letitia James said in a release that the company would have to comply with oversight measures, prevent fraudulent prescriptions and flag suspicious ones.

    Some government lawyers suggested Walmart has acted more responsibly than other pharmacies when it came to opioids.

    “Although Walmart filled significantly fewer prescriptions for opioids then CVS or Walgreens, since 2018 Walmart has been the most proactive in trying to monitor and control prescription opioid diversion attempted through its pharmacies,” Nebraska Attorney General Doug Peterson said in a statement.

    The deals are the product of negotiations with a group of state attorneys general, but they are not final. The CVS and Walgreens deals would have to be accepted first by a critical mass of state and local governments before they are completed.

    Walmart’s plan would have to be approved by 43 states by Dec. 15, and local governments could sign on by March 31, 2023. Each state’s allocation depends partly on how many local governments agree.

    “Companies like Walmart need to step up and help by ensuring Pennsylvanians get the treatment and recovery resources they need,” Pennsylvania Attorney General Josh Shapiro, who last week was elected governor of his state, said in a statement. “This deal with Walmart adds to the important progress we’ve already achieved through our settlements with the opioid manufacturers and distributors – and we’re not done yet.”

    The share of Walmart’s proposed settlement going to Native American tribes is $78 million, to be divided among all the federally recognized tribes, said Robins Kaplan, a law firm representing tribes.

    After governments used funds from tobacco settlements in the 1990s for purposes unrelated to public health, the opioid settlements have been crafted to ensure most of the money goes to fighting the crisis. State and local governments are devising spending plans now.

    Opioids of all kinds have been linked to more than 500,000 deaths in the U.S. over the past two decades.

    In the 2000s, most fatal opioid overdoses involved prescription drugs such as OxyContin and generic oxycodone. After governments, doctors and companies took steps to make them harder to obtain, people addicted to the drugs increasingly turned to heroin, which proved more deadly.

    In recent years, opioid deaths have soared to record levels, around 80,000 a year. Most of those deaths involve illicitly produced version of the powerful lab-made drug fentanyl, which is appearing throughout the U.S. supply of illegal drugs.

    [ad_2]

    Source link

  • Fatal Heart Infections Linked to Opioid Abuse Have Tripled Among Young Americans

    Fatal Heart Infections Linked to Opioid Abuse Have Tripled Among Young Americans

    [ad_1]

    By Dennis Thompson 

    HealthDay Reporter

    WEDNESDAY, Nov. 9, 2022 (HealthDay News) — The U.S. opioid epidemic has been heartbreaking — literally.

    Young adults’ risk of dying from a devastating infection of the heart has doubled to tripled in the United States during the past two decades, a new study reports.

    Researchers ascribe the increase in fatal heart infections to the growing number of people between 15 and 44 who are injecting opioid drugs.

    “We found that people who inject drugs comprise a bigger percentage of the deaths from infective endocarditis, compared to 20 years ago,” said senior researcher Dr. Polydoros Kampaktsis, an assistant professor with Columbia University’s division of cardiology, in New York City.

    “This is more notable among the younger population,” he added.

    Endocarditis occurs when the lining of your heart valves and heart chambers — the endocardium — become infected with germs, typically bacteria, that enter your bloodstream.

    If left untreated, the infection can “destroy the heart,” said Dr. Georgios Syros, director of arrhythmia services at Mount Sinai Queens in New York City.

    “You can have strokes. You can have leaking valves. You may have to do open-heart surgery to replace those valves,” Syros said. “It’s devastating.”

    The death rate for infective endocarditis among people 15 to 44 doubled between 1999 and 2020, increasing from 0.3 deaths to 0.6 deaths per 100,000 people, according to the researchers’ analysis of federal mortality data.

    Worse, the endocarditis death rate tripled for people 15 to 34, rising from 0.1 to 0.3 deaths per 100,000 people, the findings showed.

    This occurred even as the endocarditis death rate for the entire U.S. population fell, from 2.1 per 100,000 people in 1999 to 1.8 in 2020.

    Overall, young people comprised 10% of all endocarditis deaths in 2020, an increase from less than 7% in 1999, the investigators found.

    Looking more closely at the statistics, the research team concluded the opioid epidemic is likely responsible for the rise in endocarditis deaths among the young.

    People who inject drugs constitute an increasing percentage of all those who die from endocarditis, rising from 1.1% in 1999 to 3% in 2020.

    Among young people, intravenous drug users constituted nearly 20% of endocarditis deaths in 2020, up from about 10% in 1999, according to the report.

    “This is a continuation of the story of death by despair that we have seen. It is unfortunate that these data and findings confirm what we have been seeing clinically for years,” said Dr. Wael Jaber, a cardiologist with the Cleveland Clinic in Ohio.

    Humans have layers upon layers of skin and immune defenses to prevent germs from freely circulating in the bloodstream, but drug users who shoot up bypass all that protection, said Syros and Kampaktsis.

    “Intravenous injection can introduce bacteria directly to the blood circulation,” Kampaktsis explained. “Bacteria can be present in the skin or the needle. Once the needle enters the vein, it allows bacteria to enter the circulation and travel to the heart.”

    The risk is even greater given that drug users often inject themselves regularly, Syros added.

    “These guys repeatedly breach the barrier,” Syros said. “They’re not injecting once in a lifetime. They are injecting perpetually, and they’re also sharing needles. That multiplies the risk of getting exposed to something that can cause infective endocarditis.”

    Treatment options are limited, typically involving heavy doses of intravenous antibiotics, the experts said.

    “‘Sterilizing’ the bloodstream is often difficult and the risk of infection return is high, especially with continuous drug use,” Jaber said.

    If the infection has damaged the heart valves, high-risk open-heart surgery might be needed to replace them with prosthetic valves, he noted.

    “There really is no good way to ‘cure’ this heart complication,” Jaber said.

    Needle exchange programs are likely the only way to immediately address this risk to heart health, Syros said.

    “We should definitely try to give them clean syringes,” Syros said. “If you want to use, please use a clean syringe.”

    Substance abuse soared during the COVID pandemic, with an increase in fatal drug overdoses of nearly 30% during the first full year of the crisis, Syros added.

    “This is something that I have personally witnessed in the hospital,” Syros said. “There were people that were hovering there — before the pandemic, they were on the verge of using/not using drugs, drinking/not drinking alcohol. Because of the pandemic, it was like a slap, and then we saw numbers rising very, very, very fast.”

    Until the United States adopts cultural and policy changes to effectively curb opioid use, Syros believes cases of endocarditis among young drug users will continue to climb.

    “I think we’re going to have a surge in the years to come, following the increase in people taking opiates during COVID,” Syros said. “I believe there will be a wave of infective endocarditis affecting the young in the years after the pandemic. It’s going to go up.”

    The new study was published Nov. 9 in the Journal of Internal Medicine.

    More information

    The Cleveland Clinic has more on endocarditis.

     

    SOURCES: Polydoros Kampaktsis, MD, PhD, assistant professor, division of cardiology, Columbia University, Irving Medical Center, New York City; Georgios Syros, MD, director, arrhythmia services, Mount Sinai Queens, New York City; Wael Jaber, MD, cardiologist, Cleveland Clinic, Ohio; Journal of Internal Medicine, Nov. 9, 2022

    [ad_2]

    Source link

  • CVS, Walgreens And Walmart Agree To $12 Billion Global Opioid Settlement

    CVS, Walgreens And Walmart Agree To $12 Billion Global Opioid Settlement

    [ad_1]

    CVS, Walgreens and Walmart – the nation’s three largest retail U.S. pharmacy chains — have agreed “in principle” to pay $12 billion in a massive global settlement to resolve claims they contributed to the opioid epidemic.

    Bloomberg News was the first major news outlet to report Tuesday night that CVS Health, Walgreens Boots Alliance and Walmart have “tentatively agreed to pay more than $12 billion to resolve thousands of state and local government lawsuits accusing the chains of mishandling opioid painkillers.” Bloomberg cited “people familiar with the matter” as its sources on the settlement.

    The U.S. Centers for Disease Control and Prevention estimates the nationwide opioid crisis has led to more than a half million deaths from overdose in the last 20 years. Walmart, CVS and Walgreens combined have more than 23,000 U.S. pharmacies.

    None of the U.S. drugstore chains reached Tuesday night agreed to comment on the reports or a proposed settlement. CVS is scheduled to report its third quarter earnings on Wednesday when more details of its share of the potential settlement could be disclosed.

    According to reports and sources close to the companies, CVS is expected to pay $5 billion, Walgreens about $4 billion and Walmart will pay $3 billion. The settlement still has to be agreed to by the states, counties and other government entities involved in the discussions and who stand to reap the payouts.

    But none of the retail pharmacy chains are admitting to wrongdoing, according to sources close to the company and media reports Tuesday night.

    Investigations by state and federal attorneys as well as lawyers in private practices representing families of opioid victims have cited the role of distributors and pharmacies in the epidemic. A 2019 investigative report in the Washington Post said Walgreens “handled nearly one in five of the most addictive opioids” at the peak of the crisis surrounding the painkiller and acted as its “own distributor.”

    [ad_2]

    Bruce Japsen, Senior Contributor

    Source link

  • Death sentence sought for man accused of killing officer

    Death sentence sought for man accused of killing officer

    [ad_1]

    RICHMOND, Ind. — A prosecutor wants the death penalty for a man charged with killing an Indiana police officer.

    Wayne County Prosecutor Mike Shipman made the request Friday in the case of Phillip Matthew Lee, 47, of Richmond, who’s now charged with murder in the death of Richmond Police Department Officer Seara Burton.

    Burton, 28, died Sept. 18 from her gunshot wound to the head after she was taken off life support Sept. 1. She was shot Aug. 10 after other officers stopped Lee, and Burton was called to the scene to assist with her police dog.

    Court documents allege Lee pulled out a gun and fired shots toward the officers, striking Burton. Other officers returned fire, and Lee was apprehended following a foot chase.

    Online court records do not show Lee entering a plea on the murder charge. He earlier pleaded not guilty to three counts of attempted murder as well as drug and weapons charges. Lee is being held at the Miami Correctional Facility in Bunker Hill on a parole violation.

    Shipman filed court documents Friday that amended a previously filed attempted murder charge in Burton’s shooting to murder and that requests a death sentence if Lee is convicted, the Palladium-Item reported.

    Shipman’s filing indicates that two aggravating circumstances would justify the death sentence: that Lee intentionally killed Burton while she was acting in the course of her duty and that the killing occurred while Lee was free on parole after being convicted of possession of a syringe and possession of a narcotic drug.

    The prosecutor also requests Lee now be held without bond. Wayne Circuit Judge April Drake previously had set a $1.5 million bond for Lee. His trial is currently scheduled for Dec. 27.

    Shipman also filed documents that accuse Lee of being a habitual offender and for an enhancement to two remaining attempted murder charges because Lee used a firearm. The habitual offender allegation against Lee is based on four previous cases that resulted in felony convictions for burglary, possession of cocaine, attempted burglary, auto theft and resisting law enforcement, and possession of a syringe and possession of a narcotic.

    The prosecution and Lee’s court-appointed defense attorney, Andrew Maternowski, jointly filed a motion Friday for a gag order in the case.

    [ad_2]

    Source link

  • ICAIE Applauds Global Financial Integrity (GFI) in New Report on China’s Role in Transnational Crime and Illicit Trade

    ICAIE Applauds Global Financial Integrity (GFI) in New Report on China’s Role in Transnational Crime and Illicit Trade

    [ad_1]

    According to ICAIE, China Inc. has leveraged corruption, illicit markets, and predatory trade and lending practices to become the world’s biggest transnational illicit trade syndicate across global markets, supply chains, and online marketplaces, and to finance its economy and military, enhancing prosperity and anchoring stability for the ruling CCP regime.

    Press Release


    Oct 27, 2022

    David M. Luna, Executive Director of the International Coalition Against Illicit Economies (ICAIE), applauds the new report by Global Financial Integrity (GFI), “Made in China: China’s Role in Transnational Crime & Illicit Financial Flows”, which analyzes the growing illegal trade and corruptive influence by China Inc. – China’s network of state-owned enterprises and criminal triads – across markets globally.  

    “Corruption and illicit trade are among the enabling drivers of China’s national aspirations to global economic power, its aggressive foreign policy, and great power competition strategies. China’s illicit trade facilitates a convergence of crimes that spawns bigger destabilizing threats across the international community,” said Luna.

    The state-sponsored corruption exported through its strident foreign policy is sanctioned at the top level of government through China’s state-owned enterprises or external economic development initiatives such as the Belt and Road Initiative.” David M. Luna 

    China’s role in diverse forms of illicit trade and dark commerce today includes the trafficking of illegal fentanyl and precursors, humans, counterfeits, endangered wildlife, and other contraband, as well as money laundering across black markets and the digital world, as the report finds.

    As detailed in the new GFI report, “China today is helping fuel the multi-trillion-dollar global illegal economy. China is benefitting financially through the illicit manufacturing and unauthorized exporting of harmful products such as the chemical precursors to make deadly fentanyl and other opioids, fake goods that can cause great bodily harm or death, and through its international role in laundering dirty money from all corners of the globe,” said Luna.

    “Illicit activities such as the illegal fentanyl trade not only harms our people – killing tens of thousands of Americans each year – it becomes a threat multiplier. It enables Mexican cartels to earn tens of billions of dollars a year in dirty money, some of which is laundered in China, and the financing enables the cartels to infiltrate the Mexican government,” added Luna.

    The GFI report also finds that another harm to global security is driven from China’s illegal trade and unregulated economy and the flooding of counterfeits – oftentimes dangerous and toxic fake products – into U.S. markets and online marketplaces. According to estimates in the report, China accounts for up to 80% of all counterfeits in the global marketplace (OECD: $500 billion/year).

    ICAIE encourages the United States and international community to confront and constructively engage China to be a more responsible global leader and market citizen in addressing a multitude of the illicit threats that harm U.S. national security and the collective security of all nations. 

    Source: ICAIE

    [ad_2]

    Source link

  • Biking While High on Meth, Opioids Is Sending Thousands to ER

    Biking While High on Meth, Opioids Is Sending Thousands to ER

    [ad_1]

    By Steven Reinberg HealthDay Reporter

    HealthDay Reporter

    MONDAY, Sept. 26, 2022 (HealthDay News) — Biking while stoned leads to thousands of serious crashes each year, a new study suggests.

    Between 2019 and 2020 alone, more than 11,000 people were treated in U.S. emergency rooms for injuries that happened as they rode a bicycle while high on methamphetamine, marijuana or opioids, researchers found.

    “The people affected by these injuries likely have substance use disorder, may be more likely to be homeless and may not have access to other types of transportation,” explained lead researcher Bart Hammig, a professor of public health at the University of Arkansas in Fayetteville. “This is an often overlooked and ignored population when addressing serious injuries related to bicycle crashes.”

    One way to curb these crashes is to get these drugged individuals off their bikes, he said.

    “Better and easier access to transportation for persons who may use bicycles as their main mode of transportation is needed in order to aid in the prevention of injuries among this population,” he said. “In addition to treatment of injuries, drug referral systems need to be readily accessible in emergency departments.”

    Hammig and his University of Arkansas colleague Robert Davis, an assistant professor of public health, found that bicyclists who crashed while high often had more serious injuries than those who weren’t using drugs.

    Most of those injured were men (86%), according to the study. Of those, 22% had broken bones; 19% injured internal organs; and almost 33% had to be hospitalized. In all, 1% suffered a concussion.

    Some likely resulted in deaths, but because the data came from emergency room records, researchers couldn’t report on fatalities.

    The most common drugs found were methamphetamine (36%); marijuana (32%); and opioids (19%). Nearly a quarter of injured bikers had also been drinking alcohol, the study found.

    For the study, researchers used data from the National Electronic Injury Surveillance System. Of more than 480,000 injuries reported between 2019 and 2020, about 3% involved drugs.

    Dr. Eugene Vortsman, an emergency room physician at Long Island Jewish Medical Center in New Hyde Park, N.Y., said that riding a bike stoned can greatly increase the risk for crashes and serious injury.

    He suspects that the number of crashes identified in the study is only the tip of the iceberg.

    “Due to the limitations in data, this study is underestimating the true severity of the incidence, as well as the severity of injury associated with any intoxicant,” Vortsman said. “Even with the data available, it is clear that the risk of injury is elevated.”

    More study is needed to learn about bikes for primary transportation and to find ways to lower the risk, Vortsman said.

    Some examples include evaluating social factors affecting health to better earmark resources. Improving access to public transportation, better roadside safety measures, and education about the dangers of operating any mode of transportation while under the influence are key, he said.

    “Proper education allows patients to better understand their risk of injury and can provide a safer road for them as well as other bicyclists,” Vortsman said.

    The study was recently published online in the Journal of Studies on Alcohol and Drugs.

    More information

    For more about drug abuse, visit the U.S. Substance Abuse and Mental Health Services Administration.

    SOURCES: Bart Hammig, PhD, MPH, professor, health, human performance and recreation, University of Arkansas, Fayetteville; Eugene Vortsman, DO, emergency room physician, Long Island Jewish Medical Center, New Hyde Park, N.Y.; Journal of Studies on Alcohol and Drugs, Aug. 1, 2022

    [ad_2]

    Source link

  • Fentanyl pills disguised in candy bags seized at LA airport

    Fentanyl pills disguised in candy bags seized at LA airport

    [ad_1]

    LOS ANGELES — Authorities on Wednesday seized thousands of suspected fentanyl pills hidden in candy boxes at Los Angeles International Airport.

    Someone tried to go through security screening with some snacks and bags of candy at about 7:30 a.m., the Los Angeles County Sheriff’s Department said in a statement.

    “However, it was discovered that inside the ‘Sweetarts’, ‘Skittles’, and ‘Whoppers’ candy boxes were fentanyl pills,” the statement said.

    About 12,000 pills were seized by sheriff’s detectives and U.S. Drug Enforcement Administration agents assigned to a drug task force at the airport, authorities said.

    The suspected trafficker fled but has been identified, authorities said.

    Authorities recently have warned that drug dealers have been disguising fentanyl in candy wrappers and manufacturing them in rainbow colors.

    “With Halloween approaching, parents need to make sure they are checking their kids candy and not allowing them to eat anything until it has been inspected by them,” the Sheriff’s Department said.

    Parents shouldn’t touch any suspected drugs and should immediately call law enforcement, the department said.

    [ad_2]

    Source link

  • Fentanyl pills disguised in candy bags seized at LA airport

    Fentanyl pills disguised in candy bags seized at LA airport

    [ad_1]

    LOS ANGELES — Authorities on Wednesday seized thousands of suspected fentanyl pills hidden in candy boxes at Los Angeles International Airport.

    Someone tried to go through security screening with some snacks and bags of candy at about 7:30 a.m., the Los Angeles County Sheriff’s Department said in a statement.

    “However, it was discovered that inside the ‘Sweetarts’, ‘Skittles’, and ‘Whoppers’ candy boxes were fentanyl pills,” the statement said.

    About 12,000 pills were seized by sheriff’s detectives and U.S. Drug Enforcement Administration agents assigned to a drug task force at the airport, authorities said.

    The suspected trafficker fled but has been identified, authorities said.

    Authorities recently have warned that drug dealers have been disguising fentanyl in candy wrappers and manufacturing them in rainbow colors.

    “With Halloween approaching, parents need to make sure they are checking their kids candy and not allowing them to eat anything until it has been inspected by them,” the Sheriff’s Department said.

    Parents shouldn’t touch any suspected drugs and should immediately call law enforcement, the department said.

    [ad_2]

    Source link

  • Ex-Angels employee gets 22 years in Skaggs overdose death

    Ex-Angels employee gets 22 years in Skaggs overdose death

    [ad_1]

    FORT WORTH, Texas — A former Los Angeles Angels employee was sentenced to 22 years in federal prison Tuesday for providing Angels pitcher Tyler Skaggs the drugs that led to his overdose death in Texas.

    Eric Kay, dressed in an orange jumpsuit with handcuffs and leg shackles, didn’t react when U.S. District Judge Terry R. Means read his sentence. Kay faced at least 20 years in prison on one of the two counts.

    There was no reaction from Skaggs’ widow and mother or members of Kay’s family, including one of his sons who read a statement on his behalf before sentencing. A bailiff had warned observers they would be removed from the court over any outbursts.

    Prosecutors presented evidence of Kay, 48, making derogatory comments about Skaggs, his family, prosecutors and jurors in phone calls and emails after he was convicted in February.

    There was emotional testimony from both sides in federal court in Fort Worth, about 15 miles from where the Angels were supposed to open a four-game series against the Texas Rangers on July 1, 2019, the day Skaggs was found dead in a suburban Dallas hotel room.

    Kay was convicted on one count each of drug distribution resulting in death and drug conspiracy. Means recommended Kay serve his time in his home state of California. He has been in prison in Fort Worth since the conviction.

    A coroner’s report said Skaggs, 27, had choked to death on his vomit and that a toxic mix of alcohol, fentanyl and oxycodone was in his system.

    The trial included testimony from five major league players who said they received oxycodone pills from Kay at various times from 2017-19, the years Kay was accused of obtaining pills and giving them to players at Angel Stadium. Kay also used drugs himself, according to testimony and court documents.

    After revealing the sentence, Means said he dreaded this day from the beginning of the case because the 20-year minimum could be considered too harsh for the crime.

    Means said he added two years because of Kay’s comments to his family in jailhouse conversations after the conviction.

    The judge interrupted Kay to quote the former public relations employee as saying in one of those exchanges, “I’m here because of Tyler Skaggs. Well, he’s dead. So (expletive) him.”

    “That’s disgusting,” Kay responded. “I don’t know why I said that. I was mad at the world.”

    Means appeared skeptical, even saying at one point after delivering the sentence that he would probably become a target of Kay’s anger.

    The judge said Kay displayed “a callousness and refusal to accept responsibility and even be remorseful for something that you caused.”

    “Tyler Skaggs wasn’t a perfect person,” the judge said. “But he paid the ultimate price for it.”

    Kay sobbed while one of his three sons spoke to the judge from the lectern in a plea for leniency. Carli Skaggs, the widow, fought back tears much the same way she did when she testified during the trial.

    “Not only am I grieving the loss of my husband,” she said. “I’m grieving the loss of myself.”

    Defense attorney Cody Cofer, who took over after Kay’s two trial lawyers were removed, sought a motion that would have allowed Means to consider a sentence below the 20-year minimum. It was denied.

    “We are very grateful to everyone who worked so hard to investigate and prosecute Eric Kay,” the Skaggs family said in a statement. “Today’s sentencing isn’t about the number of years the defendant received. The real issue in this case is holding accountable the people who are distributing the deadly drug fentanyl.”

    Kay served as the team’s public relations contact on many road trips, and the trip to Texas was his first since returning from rehab. Kay was placed on leave shortly after Skaggs’ death and never returned to the team. He didn’t testify during his trial.

    The government argued at trial that Kay was the only one who could have given Skaggs the drugs that led to his death, that the delivery was in Texas and that fentanyl was the cause of death. Prosecutors say Kay gave Skaggs counterfeit oxycodone pills that contained fentanyl.

    ———

    More AP MLB: https://apnews.com/hub/mlb and https://twitter.com/AP—Sports

    [ad_2]

    Source link

  • Drug gang kills 20 in attack on city hall in southern Mexico

    Drug gang kills 20 in attack on city hall in southern Mexico

    [ad_1]

    SAN MIGUEL TOTOLAPAN, Mexico — A drug gang shot to death 20 people, including a mayor and his father, in the mountains of the southern Mexico state of Guerrero, officials said Thursday.

    Residents began burying the victims even as a video posted on social media showed men who identified themselves as the Tequileros gang claiming responsibility for the mass shooting.

    The Guerrero state security council said gunmen burst into the town hall in the village of San Miguel Totolapan Wednesday and opened fire on a meeting the mayor was holding with other officials.

    Among the dead were Mayor Conrado Mendoza and his father, Juan Mendoza Acosta, a former mayor of the town. Most of the other victims were believed to be local officials.

    The walls of the town hall, which were surrounded by children’s fair rides at the time, were left riddled with bullets. Totolapan is geographically large but sparsely populated mountainous township in a region known as Tierra Caliente, one of Mexico’s most conflict-ridden areas.

    There were so many victims that a backhoe was brought into the town’s cemetery to scoop out graves as residents began burying their dead Thursday. By midday, two bodies had already been buried and 10 more empty pits stood waiting.

    A procession of about 100 residents singing hymns walked solemnly behind a truck carrying the coffin of one man killed in the shooting. Once they neared the cemetery, several men hoisted the coffin out of the truck and walked with it the waiting grave. Dozens of soldiers were posted at the entrance to the town.

    Ricardo Mejia, Mexico’s assistant secretary of public safety, said the Tequileros are fighting the Familia Michoacana gang in the region and that the authenticity of the video was being verified.

    “This act occurred in the context of a dispute between criminal gangs,” Mejia said. “A group known as the Tequileros dominated the region for some time; it was a group that mainly smuggled and distributed opium, but also engaged in kidnapping, extortion and several killings in the region.”

    Totolapan was controlled for years by drug gang boss Raybel Jacobo de Almonte, known by his nickname as “El Tequilero” (“The Tequila Drinker”).

    In his only known public appearance, de Almonte was captured on video drinking with the elder Mendoza, who was then the town’s mayor-elect, in 2015. It was not clear if the elder Mendoza was there of his own free will, or had been forced to attend the meeting.

    In that video, de Almonte appeared so drunk he mumbled inaudibly and had to be held up in a sitting position by one of his henchmen.

    In 2016, Totolapan locals got so fed up with abductions by the Tequileros that they kidnapped the gang leader’s mother to leverage the release of others.

    While the Tequileros long depended on trafficking opium paste from local poppy growers, the growing use of the synthetic opioid fentanyl had reduced the demand for opium paste and lowered the level of violence in Guerrero.

    Also Wednesday, in the neighboring state of Morelos, a state lawmaker was shot to death in the city of Cuernavaca, south of Mexico City.

    Two armed men traveling on a motorcycle fatally shot state Deputy Gabriela Marín as she exited a vehicle outside a pharmacy. A person with Marín was reportedly wounded in the attack.

    “Based on the information we have, we cannot rule out a motive related to politics,” Mejia said of that killing. “The deceased, Gabriela Marín, had just taken office as a legislator in July, after another member of the legislature died, and there were several legal disputes concerning the seat.”

    The killing of Mendoza brought to 18 the number of mayors slain during the administration of President Andrés Manuel López Obrador, and the number of state lawmakers to eight, according to data from Etellekt Consultores.

    Mexico’s Congress this week is debating the president’s proposal to extend the military’s policing duties to 2028. Last month, lawmakers approved López Obrador’s push to transfer the ostensibly civilian National Guard to military control.

    While attacks on public officials are not uncommon in Mexico, these come at a time when the López Obrador’s security strategy is being sharply debated. The president has placed tremendous responsibility in the armed forces rather than civilian police for reining in Mexico’s persistently high levels of violence. He pledged to continue, saying “we have to go on doing the same things, because it has brought results.”

    López Obrador sought to blame previous administrations for Mexico’s persistent problem of violence.

    “These are (criminal) organizations that have been there for a long time, that didn’t spring up in this administration,” López Obrador said. He also blamed local people in the Tierra Caliente region for supporting the gangs — and sometimes even electing them to office.

    “There are still communities that protect these groups, and even vote them into office as authorities,” the president said.

    [ad_2]

    Source link

  • There aren’t enough facilities to treat all kids hooked on opioids | CNN Politics

    There aren’t enough facilities to treat all kids hooked on opioids | CNN Politics

    [ad_1]

    A version of this story appears in CNN’s What Matters newsletter. To get it in your inbox, sign up for free here.



    CNN
     — 

    After writing several previous newsletters on the stunning rise in opioid overdoses in the US, including among adolescents, I thought it was worth taking a look at what happens after an overdose, particularly for adolescents.

    I talked to Dr. Sivabalaji Kaliamurthy about what he’s encountering. A child and adolescent addiction psychiatrist who is board certified in general psychiatry, child psychiatry and addiction psychiatry, Kaliamurthy is also the director of the addiction clinic at Children’s National Hospital in Washington, DC.

    He told me that his clinic, which he set up in early 2022, has gone from getting one or two opioid use referrals per month to eight or more per month now, a year later.

    He particularly wanted to discuss some major news: The opioid overdose antidote naloxone, sold as Narcan, got approval from the US Food and Drug Administration on March 29, the day we talked, to be sold over the counter.

    Excerpts from our conversation, edited for flow, are below.

    WOLF: What is your reaction to Narcan being available over the counter?

    KALIAMURTHY: When I do an evaluation (of a patient), regardless of the substance use, you’re always talking about naloxone, brand name Narcan. …

    The message that I present parents with is always that it’s kind of like having a fire extinguisher at home. You hope you never need to use it, but you’re glad that you have it if you need to use it.

    Access is important. There are some controversies around increasing access to naloxone and fears that this may encourage more substance use. We have scientific research looking into this very specific question.

    And overall, there’s one study that came out this month that found that across 44 states where they increased access to naloxone for adolescents, it did not increase the rates of substance use in this population. And in some states, it actually decreased opioid use among adolescents. …

    The FDA approved the over-the-counter sale of naloxone, specifically the brand Narcan, because of how easily it can be administered. Naloxone also comes in other formulations, like injections, but Narcan is a nasal spray. We’re hoping that it will be out later this summer.

    The challenge remains how much is it going to cost? On average, it can cost anywhere between $50 to $100 right now. If it becomes over-the-counter, we don’t want insurances to stop covering [it].

    It will be interesting to see how the manufacturer goes about introducing it over the counter.

    WOLF: You said it’s like a fire extinguisher. Should everybody have it, or just people whose kids have demonstrated addictive behavior?

    KALIAMURTHY: Everyone should have it. Naloxone is not a treatment; it is more of an antidote. It reverses opioid overdoses, and the person who has the opioid overdose is never the one who’s going to use it somewhere in the community.

    WOLF: I’ve reported on a surge in overdoses. What are you seeing at Children’s?

    KALIAMURTHY: We are seeing an increase in the number of kids presenting to the hospital after experiencing an opioid overdose, and in general, opioid overdose deaths in the DMV (Washington, DC, Maryland, Virginia) region have significantly increased in the last two years. That aligns with a national trend we are seeing with regards to opioid overdoses.

    WOLF: Is there a profile for who these kids are? Do they share any traits?

    KALIAMURTHY: Yes. Let me talk about the kids we do see for opioid-related concerns first.

    At Children’s National, children often present after experiencing an overdose or having a medical complication because of using these M30, or the fake Percocet pills. We’ve had kids come in following conditions such as preliminary hemorrhage, where they were bleeding into their lungs, and overdose is not the only concern.

    Apart from that, we also have had kids presenting actively using these pills. They haven’t overdosed yet but they’re asking for help to stop using these pills.

    Some things that we have noticed, and this is the trend across the DMV region … the kids who are presenting to treatment, these are kids who are motivated to stop – they predominantly identify as Hispanic in ethnicity. Most of them have Medicaid for insurance.

    A lot of them, you know, they come to us – the average age is about 16, 16½ and their first use of opioids, these pills, was about a year ago. So the average first use was about 15 to 15½ years of age. They are really struggling, and they want to get better.

    KALIAMURTHY: Another common trait: cannabis use is quite common in this population. Pretty much every patient that I’ve come across started off around age 12 using cannabis products. This includes the flower and bud, vapes or edibles. Soon they transition to using the M30 pills.

    There are various different reasons, one of which is just access. A lot of other kids are using it. They’re using it in schools. They try it, they like it, and then it escalates and they stop using other substances.

    Most of these kids start off with crushing and try it nasally by snorting it and then they transition to smoking. What they do is they put these pills on a piece of aluminum foil, heat it up and inhale the fumes that come up. We haven’t had anyone come in who reported using any of these pills intravenously.

    WOLF: How is treatment for adolescents different than treating adult users who are seeking help?

    KALIAMURTHY: We have to take into consideration their developmental age and the psychological development that’s happening in adolescence, which is very different from adults.

    Oftentimes, this is the first point of entry into opioid use for these kids. Fentanyl, which is one of the most powerful opioids of abuse out there, is the first point of entry into opioid use for these children.

    Where for adults, they might have been prescribed pain medications. Or they might have started on opioids through other routes and might have used less potent products before transitioning to fentanyl.

    KALIAMURTHY: Historically, adolescents were not always the most motivated to seek treatment for substance use. What we would see was they would start off with experimenting, there would be a problem, it would take a few years and they’re adults by the time they’ve entered treatment and they’re trying different things to treat themselves before they enter treatment.

    With adolescents, now we are seeing that they can tell that they need help, and they are motivated and they are entering treatment.

    We have to take into account the presence of parents or guardians, how the school system interacts with them, what else do they do in their communities. There’s an increased association of violence and legal trouble that some of these patients end up in that we need to address while treating them. And these are some differences when it comes to treating adolescents versus adults.

    WOLF: One local community’s opioid response coordinator stressed to me that lack of availability of treatment is a real problem. Is that something that you agree with?

    KALIAMURTHY: Absolutely. That is a real problem at this point, because there is a huge discrepancy between the number of kids who need treatment and the available resources.

    The challenge is we can limit access and prevent these kids from getting the pills. But then you have a huge population of kids who are dependent on these pills, who can’t tolerate withdrawal symptoms, who have what we call opioid use disorder. That is going to perpetuate the problem if we’re not treating them. We need to do more in terms of increasing access to care for these kids.

    WOLF: Can you illustrate that capacity issue for me, through numbers or data? Or is it more anecdotal?

    KALIAMURTHY: Treatment is across different realms.

    For example, when a child is using these pills, and they have a problem with substance use, they need to go and be evaluated by a professional who has expertise in both addressing and evaluating mental health and addiction problems. And we don’t have very many people being able to do that.

    KALIAMURTHY: The first-time response is usually a counselor or social worker, sometimes physicians.

    But generally, there’s very little expertise in the pediatric health space with regards to addressing substance use-related problems. Screening is the point of entry.

    KALIAMURTHY: Then, say they need detox beds. Once they’ve entered treatment, we want to help them get through those initial days when their body is kind of adjusting to not using these pills, and we refer to that as detox.

    At Children’s National Hospital, when the kids come to the emergency room, we are not able to admit them for detoxes all the time. Sometimes we do end up admitting them.

    This depends on the availability of beds. The number of pediatric beds is very small to begin with. And beds may not always be available when somebody presents to the emergency room detox.

    And then there’s who is on call? Who’s available to treat these kids? I spoke about the lack of expertise in general, across the pediatric health space, so all that will determine whether a child is able to get access to detox services.

    That’s the detox part of treatment, which can be anywhere between two to five days.

    Detox doesn’t always mean somebody needs to be admitted. I also do outpatient detox where we are helping kids stop by providing them with medications and guiding their parents or guardians and the child on how to go through detox.

    KALIAMURTHY: Once you go through detox, depending on the extent of the problem, a child may require admission to a rehabilitation facility for anywhere between a month to six months.

    When we look at the number of facilities in the DMV region that provide this kind of rehab, I don’t think Virginia has any, DC doesn’t have any, Maryland has two. One is Sandstone Treatment Center, which is a private institution. The other is a treatment center, which is closer to Baltimore. There’s a limitation on who they can take.

    WOLF: Let me interrupt you. In a region that has millions of people, there are only two facilities that will take adolescents for one to six months’ treatment for substance use?

    KALIAMURTHY: Yes. For substance use.

    WOLF: Is that just a function of there’s more demand for those kinds of facilities among older people who are more likely to face addiction problems? Is that something the system is pivoting to address right now?

    KALIAMURTHY: It’s unclear. The system wants to help, but the challenge is historically adolescents are not always the most eager and motivated to get help.

    When we look at treatment programs, that didn’t exist in the past. They often relied on the judicial system, where some of these kids might have been mandated to treatment.

    Now we know that substance use disorders are chronic disorders and mandates don’t always work. Courts have stopped mandating treatment, because it’s like you mandate it for a month and then they come out and then what happens? There’s a lot of issues with mandating treatment.

    Now, most of the programs that were present prior to the pandemic also shut down during the pandemic because the needs also declined.

    This is not financially lucrative. That’s one reason why they’re having a huge issue with finding systems and having the county or the state take over with regards to creating the system.

    WOLF: I cut you off there. You were moving from the one-to-six-month facility to the next step in the process.

    KALIAMURTHY: So the next step is really engaging these kids in treatment. Not all kids require one to six months. Some kids might be OK with just completing detox and engaging in regular outpatient level of care. This might involve what we call intensive outpatient combined with medication.

    Which is where I would come in. A lot of what I do is provide medications for addiction treatment. These medications, the first part is for the detox to help with the child’s symptoms, but once you go through withdrawals, you can still have significant cravings to go back to using.

    The challenge, again, is the number of facilities. There are more options for intensive outpatient, but again, they are packed. The wait times to get in are longer now, and some of them are just virtual-only options, which may be good for some kids, but some kids might need more inpatient help.

    KALIAMURTHY: After this step, we have regular outpatient therapy and recovery support services, which is also lacking.

    The recovery support services are services which help kids get back on track academically. Catch up with your credit, get up on your grades and form a healthy, functioning resume. Get help finding part-time jobs. Keep these kids engaged in activities outside of school so that they are less likely to go back to the path that they were on which led to the substance use.

    WOLF: What’s your message to parents who are trying to keep an eye on their kids?

    KALIAMURTHY: Let’s look at the national-level data that we have collected up to 2021. Substance use is actually on the decline.

    Which is interesting because what is happening is that even though substance use among kids is on the decline – that’s both in middle school and high school – the substances that kids are using have become so much more potent.

    Take cannabis, which if you measure the potency by the percentage of THC content, has gone up significantly. The average THC percentage in the ’60s and ‘70s was like 2-5%. And now it’s like 20-25%. And kids are more likely to use what they call the concentrates, which is like 80% or more THC.

    When I talk to parents, the first thing I’m telling them about is the landscape of different substances that are out there, and kids are more likely to start off with cannabis or alcohol before they transition to the M30 pills.

    KALIAMURTHY: If you think about modifiable and non-modifiable risks, some risks just cannot be changed. These are things like genetics, family history and also if a child has a history of any traumatic experiences. Those are not things you can necessarily change. There are modifiable risk factors, like if a child has ADHD, they’re more likely to be at risk for developing substance use problems.

    If there are untreated mental health conditions, such as depression, anxiety, they’re more likely to have problems. We know that. The kids who identify as LGBTQ+, they also tend to have more risk factors in terms of initiating substances that transition into a problem.

    But also, we need to rethink how families address substances in the household. Kids learn by modeling they see from adults in their life and also the direct conversations we have. What are their values as a family around use of substances? These are not just legal and illegal – all substance use can have some harm. And early initiation is going to lead to more likelihood of having a problem.

    [ad_2]

    Source link

  • CME Activity Targets Opioid Epidemic Through Adaptive Learning

    CME Activity Targets Opioid Epidemic Through Adaptive Learning

    [ad_1]

    Press Release



    updated: Sep 23, 2019

    On each day in 2017, 91 deaths were attributed to opioid overdose; in fact, the number of overdose deaths involving opioids has increased six-fold since 1999. The numbers are clear: clinicians are failing to alleviate the nation’s growing opioid crisis. Through an adaptive-learning continuing medical education (CME) program, a collaboration of several organizations (Rockpointe, University of North Texas, CogBooks, and O’Donnell Learn) and available through the American Board of Medical Specialties (ABMS) CE Certification Directory, is offering a new approach to help clinicians turn the tide against an epidemic that has had catastrophic consequences.

    To help address the opioid crisis, the FDA developed a risk evaluation and mitigation strategy (REMS) for the use of outpatient opioid analgesics and, in 2012, issued an educational blueprint to provide guidance on prescribing opioid analgesics for pain management. In September 2018, the FDA updated the blueprint to include additional information on pain management, such as components of an effective treatment plan, non-pharmacologic treatments for pain, pharmacologic treatments for pain (non-opioid and opioid analgesics), and a primer on addiction medicine. It also widened the scope of the blueprint to apply not only to prescribers, but to all healthcare providers involved in the management of patients with pain.

    Rockpointe’s new adaptive-learning CME activity, “Opioid Analgesics: Risk Evaluation and Mitigation Strategy (REMS) and the New FDA Blueprint,” presents participating clinicians with a thorough review of the FDA’s updated educational blueprint to facilitate the evidence-based management of pain in their patients on a daily basis. The education provides tools to help clinicians mitigate issues associated with opioid therapies, such as misuse and addiction. The program aims to educate 10,000 clinicians using adaptive-learning technologies, with the results to be submitted for publication in a peer-reviewed journal.

    Physicians across many specialties manage acute and chronic pain in their patients on a daily basis. With 58 opioid prescriptions written for every 100 people in the United States in 2017, it is imperative that clinicians integrate non-pharmacologic and non-opioid analgesics into pain treatment plans in an evidence-based manner, appropriately identify patients who are candidates for opioid therapy, and recognize how to effectively monitor these patients during treatment periods. This activity is intended for those involved in direct patient care, including clinicians registered with the DEA who are eligible to prescribe all opioid analgesics. In addition, because of the broader scope of the revised FDA educational blueprint, the intended audience may include members of the healthcare team who are not authorized to prescribe.

    After completing the activity, participants should be able to:

    ·         Define the components of an effective treatment plan, such as treatment goals, patient engagement, and collaboration within the healthcare team;

    ·         Assess the risks and benefits of non-pharmacologic therapies prior to initiating long-term pharmacologic therapy;

    ·         Identify patients who are candidates for treatment with non-opioid pharmacologic analgesics;

    ·         Evaluate criteria for initiating opioid analgesics; and

    ·         Identify risk factors for addiction to opioid analgesics.

    Adaptive Learning

    The program’s adaptive-learning instructional design allows for a tailored educational experience that addresses the unique needs of each learner. The activity incorporates text, interactive questions, and audio recordings of faculty experts synced with a slide presentation. Depending on each participant’s response to the questions in the activity, an algorithm creates a unique educational pathway. Those with a good grasp of a concept move closer to completion, while others with less knowledge are provided additional content/questions to assist in gaining an adequate understanding of a topic. Post-activity content-based questions are used to assess learning, along with measures of clinicians’ perceptions of the content and their confidence in managing patients with pain.

    This CME program is available online at www.CElink.Rockpointe.com. Clinicians will be able to claim CME credit upon successful completion of the program.

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of North Texas Health Science Center (UNTHSC) and Rockpointe. UNTHSC is accredited by the ACCME to provide continuing medical education for physicians. UNTHSC designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits™.

    Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, “Opioid Analgesics: Risk Evaluation and Mitigation Strategy (REMS) and the New FDA Blueprint” has met the requirements as a MOC Part II Self-Assessment or MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

    MOC Part II Self-Assessment Activity
    Physical Medicine and Rehabilitation

    MOC Part II CME Activity
    Allergy and Immunology
    Anesthesiology
    Family Medicine
    Internal Medicine
    Medical Genetics and Genomics
    Nuclear Medicine
    Pediatrics
    Physical Medicine and Rehabilitation
    Preventive Medicine
    Psychiatry and Neurology
    Radiology
    Thoracic Surgery
    Urology

    This CME webcourse is available through Aug. 30, 2020, and the on-demand format allows participants to view the presentation at their own convenience from the comfort of their home or office.

    This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. For a list of REMS Program Companies, see: https://ce.opioidanalgesicrems.com/RpcCEUI/
    rems/pdf/resources/List_of_RPC_Companies.pdf.

    Through effective continuing medical education, Rockpointe strives to improve and advance the quality of patient care. Its educational programs have been at the forefront of new issues in healthcare, including implementing MIPS, combating the nation’s opioid crisis, and utilizing technical advances that improve care. As part of its commitment to quality, Rockpointe works to inform the continuing-education community of significant quality-improvement issues through news and analysis on Policy and Medicine. In addition, its popular Medical Education Exchange (MEDX) CME regional meetings include sessions on the basics of quality improvement and alternative payment models, as well as relevant and scientifically accurate sessions on numerous disease states. All sessions include links back to associated National Quality Priorities to reinforce the bigger picture and the triple aim of: 1) improving health and 2) lowering cost to 3) better the patient experience. At Rockpointe, education equals quality.

    Source: Rockpointe Corp

    [ad_2]

    Source link

  • Raising Awareness on the Danger of Escalating Opioid Abuse

    Raising Awareness on the Danger of Escalating Opioid Abuse

    [ad_1]

    With more Americans now dying of drug overdose than traffic accidents, the Church of Scientology Seattle and the Foundation for a Drug-Free World join forces to combat the deadly opioid epidemic.

    Press Release



    updated: Jul 26, 2017

    The Church of Scientology Seattle is sponsoring local events this summer to highlight the dangers of opioid abuse and solutions to this deadly epidemic.

    At an open forum at the Church, organized by the Foundation for a Drug-Free World, Terrie Johnston, Crime Prevention Coordinator with the Seattle Police Department, briefed community leaders on the link between drug use and crime.

    I could hold this Church up as a model for what we want every neighborhood to do.

    Terrie Johnston, Crime Prevention Coordinator with the Seattle Police Department

    As in many parts of the country, Ms. Johnston said, opioid use has been escalating in Seattle. The Washington State Department of Health reports 995 opioid-related overdose deaths from 2012 to 2016 in Seattle and the rest of King County. In that same time period, more than 1,700 died in counties across the state. And nationwide, overdoses have surpassed traffic accidents as the No. 1 cause of accidental deaths.

    Ms. Johnston indicated that the cost to the community is no less dramatic: As much as 75 percent of crimes committed in Seattle involve drugs—directly or indirectly. She also noted an increase in accident rates with a higher proportion of DUIs attributed to marijuana use.

    Ms. Johnston acknowledged the Drug-Free World volunteers for reaching out in the community with the truth about drugs. “You never know the ripple effects of what you do,” she said. “It’s been a great partnership. I could hold this Church up as a model for what we want every neighborhood to do.”

    The Church of Scientology and its members support the Foundation for a Drug-Free World, whose Truth About Drugs campaign is one of the world’s largest nongovernmental drug education and prevention initiatives. Thanks to this support, the Foundation provides—free of charge—drug education booklets, videos and educator guides to teachers, mentors and civic and community leaders.

    According to the United Nations Office on Drug Abuse and Illicit Trafficking, “Every dollar spent on prevention can save governments up to ten dollars in later costs.”

    Source: ScientologyNews.org

    [ad_2]

    Source link